Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec
NCT ID: NCT05434559
Last Updated: 2022-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
475 participants
OBSERVATIONAL
2022-02-20
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 will be included.
Glycemic control from 12 months before the switch to Insulin Degludec will be compared to glycemic control of the 12 months after the switch.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study cohort
People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 in the two participating sensors
Insulin Degludec
Switch during standard routine care to Insulin Degludec.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin Degludec
Switch during standard routine care to Insulin Degludec.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with T1D ≥2 years before switch to Insulin Degludec
* On basal-bolus insulin therapy with insulin pens ≥2 years before switch to Insulin Degludec
* ≥6 months use of Insulin Degludec at moment of datacollection
* Using continuous glucose monitoring ≥2 years before switch to Insulin Degludec
Exclusion Criteria
* People without T1D or with T1D \<2 years before switch to Insulin Degludec
* Women with T1D who are pregnant or planning pregnancy during -12 and +12 months
* Not using basal-bolus insulin therapy with insulin pens during -24 and +6 months
* Start to use non-insulin antidiabetic agents between -12 and +12 months
* Having received treatment with oral or injectable corticosteroids during -12 and +12 months
* Undergoing hemodialysis, renal transplantation, or beta cell transplantation during -12 and +12 months
* \<6 months use of Insulin Degludec at moment of datacollection
* Not using continuous glucose monitoring or \<2 years before switch to Insulin Degludec
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Antwerp
OTHER
prof dr Pieter Gillard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
prof dr Pieter Gillard
Coordinating Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitaire Ziekenhuizen Leuven
Leuven, , Belgium
University Hospital Antwerp
Wilrijk, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
De Groote R, Lefever E, Charleer S, Donne P, De Block C, Mathieu C, Gillard P. Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins. Diabetes Technol Ther. 2024 Aug;26(8):587-595. doi: 10.1089/dia.2023.0616. Epub 2024 Apr 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S66239
Identifier Type: -
Identifier Source: org_study_id